[1]钱元原.肺表面活性物质联合CPAP治疗NRDS的疗效[J].医学信息,2019,32(24):105-106.[doi:10.3969/j.issn.1006-1959.2019.24.035]
　QIAN Yuan-yuan.Efficacy of Pulmonary Surfactant Combined with CPAP in the Treatment of Neonatal Respiratory Distress Syndrome[J].Medical Information,2019,32(24):105-106.[doi:10.3969/j.issn.1006-1959.2019.24.035]
点击复制

肺表面活性物质联合CPAP治疗NRDS的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年24期
页码:
105-106
栏目:
临床研究
出版日期:
2019-12-15

文章信息/Info

Title:
Efficacy of Pulmonary Surfactant Combined with CPAP in the Treatment of Neonatal Respiratory Distress Syndrome
文章编号:
1006-1959（2019）24-0105-02
作者:
钱元原
（南通市妇幼保健院儿内科，江苏 南通 226009）
Author(s):
QIAN Yuan-yuan
(Department of Pediatrics,Nantong Maternal and Child Health Hospital,Nantong 226009,Jiangsu,China)
关键词:
新生儿呼吸窘迫综合征; 肺表面活性物质; 持续气道正压通气; 血气指标
Keywords:
Neonatal respiratory distress syndrome; Pulmonary surfactant; Continuous positive airway pressure ventilation; Blood gas index
分类号:
R725.6
DOI:
10.3969/j.issn.1006-1959.2019.24.035
文献标志码:
A
摘要:
目的 观察肺表面活性物质（PS）联合持续气道正压通气（CPAP）治疗新生儿呼吸窘迫综合征（NRDS）的疗效。方法 选择2016年6月~2019年5月我院收治的62例NRDS患儿，按随机数字表法分为对照组和观察组，各31例。对照组接受CPAP治疗，观察组在对照组基础上联合PS治疗。比较两组临床疗效、pH、动脉二氧化碳分压（PaCO2）、动脉血氧分压（PaO2）、氧合指数（OI）、住院时间及并发症发生情况。结果 观察组总有效率为93.55%，高于对照组的74.19%，差异有统计学意义（P＜0.05）；观察组pH、PaO2、OI均高于对照组，PaCO2低于对照组，差异均有统计学意义（P＜0.05）；观察组支气管肺发育不良发生率低于对照组，差异有统计学意义（P＜0.05）；两组肺不张、气胸及腹胀发生率比较，差异无统计学意义（P＞0.05）；观察组住院时间短于对照组，差异有统计学意义（P＜0.05）。结论 NRDS患儿接受PS联合CPAP治疗有利于改善动脉血气指标，提升呼吸功能，缩短住院时间，降低相关并发症发生率。
Abstract:
Objective To observe the effect of pulmonary surfactant (PS) combined with continuous positive airway pressure (CPAP) on neonatal respiratory distress syndrome (NRDS). Methods 62 children with NRDS admitted in our hospital from June 2016 to May 2019 were divided into control group and observation group according to the random number table method, with 31 cases each. The control group received CPAP treatment, and the observation group combined with PS treatment on the basis of the control group. The clinical efficacy, pH, partial arterial carbon dioxide pressure (PaCO2), partial arterial oxygen pressure (PaO2), oxygenation index (OI), length of hospital stay, and complications were compared between the two groups. Results The total effective rate in the observation group was 93.55%, which was higher than 74.19% in the control group,the differences were statistically significant (P<0.05). The pH, PaO2, and OI in the observation group were higher than the control group, PaCO2 was lower than the control group, the differences were statistically significant(P<0.05);The incidence of bronchopulmonary dysplasia in the observation group was lower than that in the control group,the difference was statistically significant (P<0.05). There was no significant difference in the incidence of atelectasis, pneumothorax, and abdominal distension in the two groups (P>0.05). The length of hospital stay was shorter than that of the control group,the difference was statistically significant (P<0.05). Conclusion Children with NRDS receiving PS combined with CPAP can improve arterial blood gas parameters, improve respiratory function, shorten hospital stay, and reduce the incidence of related complications.

参考文献/References:

[1]马红茹,吕菊红,李冬梅,等.CPAP联合不同剂量肺表面活性物质对新生儿呼吸窘迫综合征脑氧代谢的影响[J].广西医科大学学报,2019,36(2):285-289.[2]廖亮荣.机械通气与经鼻塞持续正压通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征的疗效分析[J].中国妇幼保健,2018,33(2):432-434.[3]邵肖梅,叶鸿瑁,丘小汕.实用新生儿学[M].第4版.北京:人民卫生出版社,2011:347-351.[4]娄五斌,张卫星.经鼻无创高频振荡通气和持续气道正压通气在早产儿呼吸窘迫综合征撤机后的应用比较[J].广东医学,2017,38(13):2037-2040.

相似文献/References:

[1]王 瑜.猪肺磷脂注射液联合无创通气治疗新生儿呼吸窘迫综合征的疗效[J].医学信息,2022,35(10):143.[doi:10.3969/j.issn.1006-1959.2022.10.035]
　WANG Yu.Effect of Porcine Pulmonary Phospholipid Injection Combined with Noninvasive Ventilation on Neonatal Respiratory Distress Syndrome[J].Medical Information,2022,35(24):143.[doi:10.3969/j.issn.1006-1959.2022.10.035]
[2]孙继飞,张 岚.肺表面活性物质治疗足月新生儿急性呼吸窘迫综合征疗效观察[J].医学信息,2019,32(02):121.[doi:10.3969/j.issn.1006-1959.2019.02.034]
　SUN Ji-fei,ZHANG Lan.Therapeutic Effect of Pulmonary Surfactant on Acute Respiratory Distress Syndrome in Full-term Neonates[J].Medical Information,2019,32(24):121.[doi:10.3969/j.issn.1006-1959.2019.02.034]
[3]魏 颖,罗 芳.CPAP联合不同时间应用肺表面活性物质对早产呼吸窘迫综合征患儿预后的影响[J].医学信息,2022,35(19):92.[doi:10.3969/j.issn.1006-1959.2022.19.025]
　WEI Ying,LUO Fang.Effect of CPAP Combined with Different Time Application of Pulmonary Surfactant on Prognosis of Premature Infants with Respiratory Distress Syndrome[J].Medical Information,2022,35(24):92.[doi:10.3969/j.issn.1006-1959.2022.19.025]
[4]饶 军,程贤高,李晓春,等.布地奈德联合肺表面活性物质气管内注入防治早产儿支气管肺发育不良的效果[J].医学信息,2020,33(23):147.[doi:10.3969/j.issn.1006-1959.2020.23.043]
　RAO Jun,CHENG Xian-gao,LI Xiao-chun,et al.Effect of Intratracheal Injection of Budesonide Combined with Pulmonary Surfactant in the Prevention and Treatment of Bronchopulmonary Dysplasia in Premature Infants[J].Medical Information,2020,33(24):147.[doi:10.3969/j.issn.1006-1959.2020.23.043]
[5]童 玲,王慧琴.基于Logistic回归模型的足月新生儿呼吸窘迫综合征相关因素分析[J].医学信息,2020,33(19):91.[doi:10.3969/j.issn.1006-1959.2020.19.026]
　TONG Ling,WANG Hui-qin.Analysis of Related Factors of Full-term Neonatal Respiratory Distress Syndrome Based on Logistic Regression Model[J].Medical Information,2020,33(24):91.[doi:10.3969/j.issn.1006-1959.2020.19.026]
[6]郭杨杨,余加林.肺表面活性物质在重症新生儿呼吸窘迫综合征中的应用[J].医学信息,2018,31(09):42.[doi:10.3969/j.issn.1006-1959.2018.09.014]
　GUO Yang-yang,YU Jia-lin.Application of Pulmonary Surfactant in Severe Neonatal Respiratory Distress Syndrome[J].Medical Information,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.09.014]

更新日期/Last Update: 2019-12-15